Global Custom Market Research Reports Provider Company

phone

Hypoglycemia - Pipeline Review, H2 2017

  • Published Date: 18 Jul 2017
  • Number of Pages: 80
  • Category: Pharmaceuticals
  • Country: Global
Hypoglycemia - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H2 2017, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 2, 6, 5, 3 and 2 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Publisher Name : Global Markets Direct

Introduction 5
Global Markets Direct Report Coverage 5
Hypoglycemia - Overview 6
Hypoglycemia - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 10
Hypoglycemia - Therapeutics Assessment 12
Assessment by Target 12
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Hypoglycemia - Companies Involved in Therapeutics Development 20
Adocia SAS 20
Arecor Ltd 20
Eiger BioPharmaceuticals Inc 21
Eli Lilly and Company 21
Heptares Therapeutics Ltd 22
LATITUDE Pharmaceuticals Inc 22
Novartis AG 23
Therakind Ltd 23
USV Pvt Ltd 24
Vectura Group Plc 24
XERIS Pharmaceuticals Inc 25
XOMA Corp 25
Zealand Pharma AS 26
Zucara Therapeutics Inc 26
Hypoglycemia - Drug Profiles 27
(glucagon + GLP-1) - Drug Profile 27
(insulin human + pramlintide) - Drug Profile 28
dasiglucagon - Drug Profile 29
Drug for Hypoglycemia - Drug Profile 33
exendin-(9-39) - Drug Profile 34
glucagon - Drug Profile 37
glucagon - Drug Profile 41
glucagon - Drug Profile 42
glucagon - Drug Profile 43
glucagon biosimilar - Drug Profile 44
LY-3143753 - Drug Profile 45
LY-3185643 - Drug Profile 46
LY-900018 - Drug Profile 47
pasireotide - Drug Profile 49
PRL-2903 - Drug Profile 53
Recombinant Peptide 1 to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile 54
Recombinant Peptide to Agonize Glucagon Receptor for Hypoglycemia - Drug Profile 55
Small Molecule to Antagonize GLP-1 Receptor Hypoglycemia and Congenital Hyperinsulinism - Drug Profile 56
terbutaline sulphate MR - Drug Profile 57
XOMA-129 - Drug Profile 58
XOMA-358 - Drug Profile 59
Hypoglycemia - Dormant Projects 62
Hypoglycemia - Discontinued Products 63
Hypoglycemia - Product Development Milestones 64
Featured News & Press Releases 64
Appendix 77
Methodology 77
Coverage 77
Secondary Research 77
Primary Research 77
Expert Panel Validation 77
Contact Us 77
Disclaimer 78

List Of Tables


Number of Products under Development for Hypoglycemia, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Hypoglycemia - Pipeline by Adocia SAS, H2 2017
Hypoglycemia - Pipeline by Arecor Ltd, H2 2017
Hypoglycemia - Pipeline by Eiger BioPharmaceuticals Inc, H2 2017
Hypoglycemia - Pipeline by Eli Lilly and Company, H2 2017
Hypoglycemia - Pipeline by Heptares Therapeutics Ltd, H2 2017
Hypoglycemia - Pipeline by LATITUDE Pharmaceuticals Inc, H2 2017
Hypoglycemia - Pipeline by Novartis AG, H2 2017
Hypoglycemia - Pipeline by Therakind Ltd, H2 2017
Hypoglycemia - Pipeline by USV Pvt Ltd, H2 2017
Hypoglycemia - Pipeline by Vectura Group Plc, H2 2017
Hypoglycemia - Pipeline by XERIS Pharmaceuticals Inc, H2 2017
Hypoglycemia - Pipeline by XOMA Corp, H2 2017
Hypoglycemia - Pipeline by Zealand Pharma AS, H2 2017
Hypoglycemia - Pipeline by Zucara Therapeutics Inc, H2 2017
Hypoglycemia - Dormant Projects, H2 2017
Hypoglycemia - Discontinued Products, H2 2017

List Of Figures


Number of Products under Development for Hypoglycemia, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Hypoglycemia - Pipeline Review, H2 2017 Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H2 2017, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline

View Report

Hypoglycemia Global Clinical Trials Review, H1, 2014 market research report at USD 2500 and market update available at JSB Market Research.

View Report
There is no reviews available for this report

Select License Type

Delivery Details

Delivery Details : Electronic files (PDF) of market research reports will dispatched within 12 to 24 hours. (Mon-Fri IST)

Customized Report

If a particular report is not as per your requirement you can ‎choose "Customized Report". To visit click on -

Custom Research Reports